Exelixis EXEL License revenues — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's license revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's license revenues — total revenues?
- Exelixis (EXEL) reported license revenues — total revenues of $56.95M in Q1 2026.
- How has Exelixis's license revenues — total revenues changed year-over-year?
- Exelixis's license revenues — total revenues increased by 34.1% year-over-year, from $42.48M to $56.95M.
- What is the long-term trend for Exelixis's license revenues — total revenues?
- Over 4 years (2021 to 2025), Exelixis's license revenues — total revenues has grown at a -3.8% compound annual growth rate (CAGR), from $249.96M to $214.38M.
- What does license revenues — total revenues mean?
- The total income generated from licensing intellectual property and partnership agreements.
- How do you interpret license revenues — total revenues?
- An increase indicates successful monetization of the R&D pipeline or strong commercial performance by partners, while a decrease may signal expiring patents or reduced partnership activity.
- How does license revenues — total revenues compare across companies?
- Comparable to 'Collaboration and License Revenue' or 'Royalty Revenue' reported by other biotechnology companies with partnership-heavy business models.